|
Open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with oxaliplatin and 5-fluorouracil/folinic acid followed by curative surgical resection in patients with hepatic oligometastatic adenocarcinoma of the pancreas (HOLIPANC). |
|
|
Research Funding - SERVIER |
Travel, Accommodations, Expenses - SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - ClinAssess |
|
Consulting or Advisory Role - ClinAssess |
Travel, Accommodations, Expenses - CanBas |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Intuitive Surgical; Medtronic; Sirtex Medical |
Consulting or Advisory Role - Medtronic |
Research Funding - Intuitive Surgical; SERVIER; Sirtex Medical |
Travel, Accommodations, Expenses - Medtronic |
|
|
No Relationships to Disclose |